Under normal conditions, AKT inhibits GSK‐3β activity to increase insulin sensitivity, whereas under CKD, the inhibition of AKT activation by uremic toxins leads to insulin resistance by activating GSK‐3β.25 The gene discussed is AKT1; the disease is Insulin resistance.